Multi-local and serial cross-sectional prevalence study on antibodies against SARS-CoV-2 in Germany
Ongoing research shows that the number of non-reported COVID-19 cases is high due to mild or asymptomatic infections. As a result, it is difficult to estimate the number of individuals infected with SARS-CoV-2 and, hence, its mortality rate. Gaps in information have proven to be a strong liability in the context of epidemics, challenging public health decision making and real-time tracking of changes.
At the Helmholtz Centre for Infection Research (HZI), the Department of Epidemiology has designed a population-specific field-based seroprevalence study in Germany. In partnership with researchers and on-site public health agents, this cross-sectional study aims at detecting specific antibodies against SARS-CoV-2 in human blood samples collected from district-level populations. Thus, it is possible to identify infected individuals via antibody detection, even if they have never received a positive test result nor experienced any symptoms. Moreover, it will be possible to identify potential risk- and protective factors, via the collection of epidemiological data, such as demography, clinical history and living conditions. Selected districts will receive follow-up visits to collect information on the course of the immune response.
The nationwide antibody study started on July 1 in Reutlingen as a pilot region.
If you take part in the study and have further questions about it, contact us via:
- Phone +49 531 6181 3160 or
- E-mail to email@example.com
Helmholtz Association of German Research Centers